Patience running out for Woodford trust as largest holding hit
This week has brought more bad news for Neil Woodford’s Patient Capital Trust, as shares in his largest holding Prothena tanked.
This week has brought more bad news for Neil Woodford’s Patient Capital Trust, as shares in his largest holding Prothena tanked.
Neil Woodford has added to his position in UK banks, with both Barclays and RBS appearing in his portfolios he revealed on Thursday.
Neil Woodford has added UK media giant ITV to his income focus fund claiming its current value is an “attractive entry point”.
On 22 August, doorstep lender Provident Financial hit investors with a devastating triple-whammy – a profit warning (its second in a matter of months), an FCA investigation into its credit card subsidiary Vanquis Bank and the resignation of disgraced CEO Peter Crook.
The managers of the Walker Crips managed portfolio range are sticking with Neil Woodford despite an extremely tough few months for the star manager.
While Fundsmith Equity, Woodford Income and Lindsell Train Global were the most popular funds in September, Vanguard “muscled its way in to the top five”, according to Interactive Investor.
Neil Woodford’s flagship Equity Income fund has been removed from FE’s approved list amid concerns over its “illiquid” investments and replaced by his recently launched Income Focus fund.
Negative updates and rocky company accounting during quiet summer months should not be a sole signal to sell a stock, says SVM Asset Management’s Margaret Lawson.
Neil Woodford has spoken out about his fund’s “incredibly painful” recent underperformance and promised to recover the capital lost in a newly released in-depth interview.
Small and expensive, are funds that have failed to hit £10m ($13m, €11m) in assets just clogging up the investment universe?
Neil Woodford dropped British American Tobacco from his flagship equity fund in June, a stock which had enjoyed a consistent place in his strategies throughout his career.
Neil Woodford’s flagship fund found its footing in February and broke the £10bn ($12.4bn, €11.5bn) barrier as the reflation trade began to lose its shine.